Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020;152(1 & 2):119-120.
doi: 10.4103/ijmr.IJMR_2372_20.

Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers

Habib M R Karim  1 , Ghazal Ahmed  2
Affiliations
Comment

Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers

Habib M R Karim et al. Indian J Med Res. 2020.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Comment in

  • Authors' response.
    Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, Singh H, Praharaj I, Gangakhedkar RR, Bhargava B, Panda S. Chatterjee P, et al. Indian J Med Res. 2020 Jul & Aug;152(1 & 2):120. doi: 10.4103/0971-5916.290073. Indian J Med Res. 2020. PMID: 32773411 Free PMC article. No abstract available.

Comment on

References

    1. Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151:459–67. - PMC - PubMed
    1. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020;S1473-3099(20):30313–3. - PMC - PubMed
    1. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents. 2020;55:105988. - PMC - PubMed
    1. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020 NEJMoa2016638. - PMC - PubMed

Substances